HAEMATO AG (HAM:HAEK)

Market Cap	43.91M
Revenue (ttm)	260.81M
Net Income (ttm)	9.61M
Shares Out	5.23M
EPS (ttm)	1.88
PE Ratio	4.48
Forward PE	n/a
Dividend	0.04 (0.48%)
Ex-Dividend Date	Jul 16, 2025

Volume	124
Average Volume	880
Open	8.25
Previous Close	8.30
Day's Range	8.25 - 8.40
52-Week Range	8.20 - 14.20
Beta	0.21
RSI	40.78
Earnings Date	n/a

About HAEMATO AG

HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. Further, the company develops, manufactures, and distributes diagnostic tests under the HAEMATO...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 1993
• Employees: 76
• Stock Exchange: Hamburg Stock Exchange
• Ticker Symbol: HAEK

Financial Performance

In 2022, HAEMATO AG's revenue was 248.14 million, a decrease of -12.95% compared to the previous year's 285.04 million. Earnings were 8.19 million, an increase of 25.39%.